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Septicemia caused by tick-borne bacterial pathogen Candidatus
Neoehrlichia mikurensis
Abstract
We have repeatedly detected Candidatus Neoehrlichia mikurensis, a bacterium first described in Rattus
norvegicus rats and Ixodes ovatus ticks in Japan in 2004 in the blood of a 61-year-old man with signs of
septicemia by 16S rRNA and groEL gene PCR. After 6 weeks of therapy with doxycycline and
rifampin, the patient recovered.
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We have repeatedly detected Candidatus Neoehrlichia 
mikurensis, a bacterium fi rst described in Rattus norvegicus 
rats and Ixodes ovatus ticks in Japan in 2004 in the blood 
of a 61-year-old man with signs of septicemia by 16S rRNA 
and groEL gene PCR. After 6 weeks of therapy with doxy-
cycline and rifampin, the patient recovered.
Since the novel bacterial genus Neoehrlichia was fi rst described in 2004, its pathogenic role in humans 
has remained unexplained (1). Related bacteria such as 
Ehrlichia chaffeensis and Anaplasma phagocytophilum are 
emerging tick-borne human pathogens that cause mono-
cytic and granulocytic ehrlichiosis, respectively. These 
tick-borne diseases manifest themselves as febrile illness, 
mild transient hepatitis, transient thrombocytopenia, and 
occasionally as a rash. The family Anaplasmataceae com-
promises the genera Ehrlichia, Anaplasma, Neorickettsia, 
and Aegyptianella, and the proposed genus Neoehrlichia. 
These are all obligate intracellular bacteria, which current-
ly are diffi cult or impossible to isolate and culture (2). In-
fections caused by agents of this bacterial family have been 
recognized as an emerging problem in the past 2 decades, 
possibly due to ecologic changes and the resulting expan-
sion of tick populations (3).
Case Report
In August 2009, a 61-year-old Caucasian man who 
lived in Switzerland sought treatment at the emergency 
department of University Hospital in Zurich, reporting a 
10-day history of malaise, temperature as high as 39.5°C, 
chills, and moderate dyspnea. Six weeks previously, he had 
undergone coronary artery bypass graft surgery and mi-
tral valve reconstruction for which prosthetic material was 
used. The patient had not noticed tick bites or a skin rash; 
neither did he recall a rodent bite. A pet dog and cat lived 
in his household. 
Physical examination showed a reduced general health 
condition and a temperature of 38.5°C. Blood pressure was 
109/68 mm Hg, heart rate was 86 beats/min, and oxygen 
saturation was 95% with 2 L nasal oxygen. No murmur 
was detected on cardiac auscultation. No skin or joint ab-
normalities were found. Laboratory tests showed elevated 
leukocytes (12.9 × 103 cells/μL), with a high fraction of 
neutrophils (10.1 × 103 cells/μL) and thrombocyte count 
within reference range (277 × 103 cells/μL); aminotrans-
ferase levels within reference ranges (aspartate aminotrans-
ferase 18 U/L, alanine aminotransferase 20 U/L); and an 
elevated C-reactive protein (CRP) of 68 mg/L (reference 
range <5 mg/L). Chest radiograph showed no signs of car-
diac decompensation or of pulmonary infi ltrates. Transtho-
racic echocardiograph showed only minor insuffi ciency of 
the aortic and tricuspid valves. In addition, degenerative 
alterations of aortic valve, but no vegetations, were noted 
with comparable fi ndings in the follow-up echocardiograph 
1 week later.
At the follow-up visit, no hints of infectious foci were 
found. Five sets of blood cultures were drawn with >12 h dif-
ference between the fi rst and the last set. Antimicrobial drug 
treatment for endocarditis with prosthetic material, consist-
ing of vancomycin, gentamicin, and rifampin, was initiated.
Blood cultures remained negative for microbial growth, 
even after extended incubation. Serologic tests for agents of 
culture-negative endocarditis and tick-borne diseases were 
performed. Enzyme immunoassays (EIAs) were positive for 
immunoglobulin (Ig) G antibodies reactive to Bartonella 
henselae (512) and B. quintana (1,024), Coxiella burnetii 
(phase II IgG titer 160), Rickettsia rickettsii/conorii (IgG 
256), and Rickettsia typhi (IgG 128), Mycoplasma pneumo-
niae (index 2.7). IgM was positive only for A. phagocyto-
philum (512, atypical fl uorescence pattern), presenting a low 
titer of IgG at this stage. Serologic test results for Brucella 
spp., Chlamydia trachomatis, Chlamydia pneumoniae, and 
Borrelia burgdorferi were negative. Species-specifi c PCRs 
for A. phagocytophilum, Tropheryma whipplei, B. hense-
lae, B. quintana, Legionella spp., and L. pneumophila were 
negative.
Bacterial broad-spectrum 16S rRNA gene PCR, fol-
lowed by sequence analysis, identifi ed Candidatus Neoeh-
rlichia mikurensis in 4 of 8 sequential blood samples; the 4 
samples that tested positive were collected before (day 0) 
and during the initial phase (days 7 and 13) of an effective 
course of antimicrobial drug therapy (Figure 1). For 16S 
rRNA gene amplifi cation, DNA was extracted and ampli-
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fi ed from anticoagulated blood (4-mL EDTA tubes), un-
coagulated blood from a BacT/ALERT SA aerobic blood 
culture fl ask (bioMérieux SA, Geneva, Switzerland), and 
coagulated blood (online Technical Appendix, www.cdc.
gov/eid/content/16/7/1127-Techapp.pdf) as described (4). 
Sequences derived (GenBank accession nos. GQ501089-
GQ501091) were analyzed by SmartGene IDNS software 
(Zug, Switzerland). We amplifi ed and sequenced (1,150 bp; 
GenBank accession no. HM045824) an alternative target 
gene (groEL) with primers (online Technical Appendix) 
derived from published sequences (1), which showed 98% 
homology to previously published Candidatus Neoehrli-
chia mikurensis groEL sequences (Figure 2, panel B).
After being treated with vancomycin, gentamicin, 
and rifampin for 10 days, the patient became afebrile, and 
clinical symptoms improved. Leukocyte count was within 
reference range, and CRP dropped from 68 mg/L to 23 
mg/L. At this time, Candidatus Neoehrlichia mikurensis 
was detected in the fi rst blood sample. Rifampin (450 mg 
2×/d) was continued, and vancomycin and gentamicin were 
switched to oral doxycycline (100 mg 2×/d). Three weeks 
later, CRP was 1 mg/L, body temperature was within the 
normal range, and treatment was continued to fi nish a 
6-week course. Two weeks after the end of treatment, the 
patient was seen for a follow-up visit. Neither clinical nor 
laboratory results raised any concern of relapse. Results of 
broad-range PCR of the 16S rRNA gene to detect Candi-
datus Neoehrlichia mikurensis were negative for the fi rst 
time in 5 weeks since treatment began initiation and re-
mained negative at the follow-up visit 2 weeks after the 
end of treatment.
Candidatus Neoehrlichia mikurensis was previously 
found in Rattus norvegicus rats and Ixodes ovatus ticks 
in Japan (1), in R. norvegicus rats in China (5), and in I. 
ricinus ticks in the Netherlands (6,7), Slovakia (8), and the 
Asian part of Russia (9). Closely related rickettsial bacteria 
(Figure 2) have been identifi ed in Procyon lotor raccoons 
in the Piedmont region of Georgia, USA (10). Another 
closely related species (Candidatus Ehrlichia walkeri) has 
been detected in I. ricinus ticks collected from humans in 
northern Italy (11). The geographic distribution of the tick 
population has also been studied (12).
Our patient lives in a high-risk area for ticks in Swit-
zerland. I. ricinus is the main tick species in this region. A 
tick-borne disease appears epidemiologically possible in this 
patient, who is a golfer and the owner of a large garden and 
thus is repeatedly exposed to the habitat of the potential vec-
tor, I. ricinus, even though he remembered no tick bites. Of 
note, only 50%–70% of patients with Lyme disease remem-
ber receiving a tick bite (13). Blood of the patient’s pet ani-
mals (dog and cat) was examined by broad-range 16S rRNA 
gene PCR to exclude presence of bacterial pathogens.
DISPATCHES
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Figure 1. Polyacrylamide gel electrophoresis analysis of broad 
range 16S rRNA gene PCR products obtained from blood samples. 
Lane 1, marker, 100 bp DNA ladder (Roche DNA Marker XIV); lane 
2, positive control, Escherichia coli; following lanes, PCR products 
obtained from blood specimens arranged by date of collection. For 
each specimen PCR products are shown obtained with undiluted 
(0) and 5×-diluted (5) DNA extracts. The 2 last negative samples 
are not shown.
Figure 2. A) Phylogenetic tree based on the 16S rRNA gene sequences of Candidatus Neoehrlichia mikurensis GQ501090.2 (our patient’s 
isolate, herein termed Zurich and indicated in boldface) and related organisms. The number at nodes indicates percentages of bootstrap 
support based on 10,000 replicates. Scale bar indicates 0.02 substitutions per nucleotide position. B) Phylogenetic tree based on the 
groEL sequences. Scale bars indicate 0.05 substitutions per nucleotide position.
Septicemia and Candidatus Neoehrlichia mikurensis
In Wister rats, Candidatus Neoehrlichia mikurensis 
has been shown to infect spleen sinus endothelial cells, 
forming intracellular inclusions on the side of the endo-
some (by electron microscopy 60 days after infection) (1). 
Accordingly, we assumed that in human hosts, valvular 
endothelial cells are likely involved. The initial antimicro-
bial drug therapy, which contained rifampin, may already 
have contributed to the reduction of the bacterial load but 
was not completely effective (Figure 1). Thus, following 
the recommended guidelines for treatment of intracellu-
lar rickettsial bacteria with endocardial involvement, we 
changed to a 6-week course of treatment consisting of ri-
fampin combined with doxycycline (14). After the end of 
the course, we observed a successful response.
We detected Candidatus Neoehrlichia mikurensis in 
4 of 8 consecutive blood specimens, and repeated analysis 
showed the disappearance of the pathogen’s DNA during the 
course of treatment (Figure 1). Laboratory diagnosis of ehrli-
chiosis is severely hampered because the relevant pathogens 
cannot be cultured on routine media. Serologic tests depend 
on samples collected during acute phase of illness, obtaining 
comparative samples in the course of the disease, and dem-
onstrating a >4-fold increase in antibody titers.
Conclusions
We have identifi ed Candidatus Neoehrlichia miku-
rensis in multiple blood samples of a patient who sought 
treatment for septicemia. Therapeutic success has been 
shown over time by the fact that the suggested pathogen’s 
DNA was no longer detectable and by a favorable clinical 
outcome. Surveys of arthropod populations should be con-
ducted to examine the geographic distribution of Candida-
tus Neoehrlichia mikurensis, and species-specifi c assays 
could determine the relevance of this organism in human 
ehrlichial diseases.
Acknowledgments
We thank Erik C. Böttger for continuous support, advice, and 
comments on the manuscript. We also thank the Institute of Clini-
cal Microbiology and Immunology, St. Gallen, for help with My-
coplasma serology; the Institut Central des Hôpitaux du Valais, 
Sion, for help with Coxiella serology; Logolab AG, Kilchberg, 
Switzerland, for help with Anaplasma serology; and C. Silaghi for 
help with A. phagocytophilum species-specifi c PCR.
Dr Fehr is an infectious disease specialist and attending phy-
sician at the University Hospital of Zurich. His research interests 
include bacterial pathogens and HIV/AIDS. He has investigated 
surgical site infections and emerging pathogens in Tanzania.
Dr Bloemberg is head of the Department of Molecular Di-
agnostics at the Institute of Medical Microbiology, University 
of Zurich. He is a specialist in molecular genetics and microbial 
biochemistry. His research interests include bacterial pathogens, 
biofi lms, antibacterial drugs, and antibiotic resistance.
References
  1.  Kawahara M, Rikihisa Y, Isogai E, Takahashi M, Misumi H, Suto 
C, et al. Ultrastructure and phylogenetic analysis of ‘Candidatus 
Neoehrlichia mikurensis’ in the family Anaplasmataceae, isolated 
from wild rats and found in Ixodes ovatus ticks. Int J Syst Evol Mi-
crobiol. 2004;54:1837–43. DOI: 10.1099/ijs.0.63260-0
  2.  Dumler JS, Madigan JE, Pusterla N, Bakken JS. Ehrlichioses in hu-
mans: epidemiology, clinical presentation, diagnosis, and treatment. 
Clin Infect Dis. 2007;45(Suppl 1):S45–51. DOI: 10.1086/518146
  3.  Estrada-Pena A. Tick-borne pathogens, transmission rates and cli-
mate change. Front Biosci. 2009;14:2674–87. DOI: 10.2741/3405
  4.  Bosshard PP, Kronenberg A, Zbinden R, Ruef C, Böttger EC, Al-
twegg M. Etiologic diagnosis of infective endocarditis by broad-
range polymerase chain reaction: a 3-year experience. Clin Infect 
Dis. 2003;37:167–72. DOI: 10.1086/375592
  5.  Pan H, Liu S, Ma Y, Tong S, Sun Y. Ehrlichia-like organism gene 
found in small mammals in the suburban district of Guangzhou of 
China. Ann N Y Acad Sci. 2003;990:107–11. DOI: 10.1111/j.1749-
6632.2003.tb07346.x
  6.  Schouls LM, Van De Pol I, Rijpkema SG, Schot CS. Detection and 
identifi cation of Ehrlichia, Borrelia burgdorferi sensu lato, and 
Bartonella species in Dutch Ixodes ricinus ticks. J Clin Microbiol. 
1999;37:2215–22.
  7.  van Overbeek L, Gassner F, van der Plas CL, Kastelein P, Nunes-
da Rocha U, Takken W. Diversity of Ixodes ricinus tick–associated 
bacterial communities from different forests. FEMS Microbiol Ecol. 
2008;66:72–84. DOI: 10.1111/j.1574-6941.2008.00468.x
  8.  Spitalska E, Boldis V, Kostanova Z, Kocianova E, Stefanidesova K. 
Incidence of various tick-borne microorganisms in rodents and ticks 
of central Slovakia. Acta Virol. 2008;52:175–9.
  9.  Rar VA, Fomenko NV, Dobrotvorsky AK, Livanova NN, Rudakova 
SA, Fedorov EG, et al. Tickborne pathogen detection, Western Sibe-
ria, Russia. Emerg Infect Dis. 2005;11:1708–15.
10.  Dugan VG, Gaydos JK, Stallknecht DE, Little SE, Beall AD, Mead 
DG, et al. Detection of Ehrlichia spp. in raccoons (Procyon lotor) 
from Georgia. Vector Borne Zoonotic Dis. 2005;5:162–71. DOI: 
10.1089/vbz.2005.5.162
11.  Brouqui P, Sanogo YO, Caruso G, Merola F, Raoult D. ‘Candida-
tus Ehrlichia walkerii’: a new Ehrlichia detected in Ixodes ricinus 
tick collected from asymptomatic humans in northern Italy. Ann 
N Y Acad Sci. 2003;990:134–40. DOI: 10.1111/j.1749-6632.2003.
tb07352.x
12.  Koutaro M, Santos AS, Dumler JS, Brouqui P. Distribution of 
‘Ehrlichia walkeri’ in Ixodes ricinus (Acari: Ixodidae) from 
the northern part of Italy. J Med Entomol. 2005;42:82–5. DOI: 
10.1603/0022-2585(2005)042[0082:DOEWII]2.0.CO;2
13.  Hengge UR, Tannapfel A, Tyring SK, Erbel R, Arendt G, Ruzicka T. 
Lyme borreliosis. Lancet Infect Dis. 2003;3:489–500. DOI: 10.1016/
S1473-3099(03)00722-9
14.  Parola P, Davoust B, Raoult D. Tick- and fl ea-borne rickettsial 
emerging zoonoses. Vet Res. 2005;36:469–92. DOI: 10.1051/
vetres:2005004
Address for correspondence: Guido V. Bloemberg, University of Zurich, 
Institute of Medical Microbiology, Gloriastrasse 32, 8006 Zurich, 
Switzerland; email: bloemberg@imm.uzh.ch
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 16, No. 7, July 2010 1129 
